Back to search

Article

Clinico-pathological factors and 18 F-FDG PET/CT metabolic parameters for prediction of progression-free survival in Radioiodine Refractory Differentiated Thyroid Carcinoma

2024-08-26

Abstract excerpt

<title>Abstract</title> <p>Objective Identifying prognostic markers for clinical outcomes is crucial for selecting appropriate treatment options for patients with radioiodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC). The aim of this study was to investigate the prognostic value of clinico-pathological features and quantitative <sup>18</sup>F-FDG PET/CT metabolic parameters in predicting progress...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
958c7c84-4617-5d91-929b-df367abe21fb
DOI
10.21203/rs.3.rs-4759823/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinico-pathological factors and 18 F-FDG PET/CT metabolic parameters for prediction of progression-free survival in Radioiodine Refractory Differentiated Thyroid CarcinomaDOI 10.21203/rs.3.rs-4759823/v1
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.Semantic proximity
Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.Semantic proximity
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.Semantic proximity
Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.Semantic proximity
Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.Semantic proximity
FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Semantic proximity
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Semantic proximity
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Semantic proximity
Glucose Metabolic Reprogramming in Thyroid Cancer: Underlying Molecular Mechanisms and Links to Progression and Treatment.Semantic proximity
Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.Semantic proximity
Select a neighboring publication to make it the new centre.